Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other equities analysts have also recently issued reports on CTSO. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Up 1.8 %

Cytosorbents stock opened at $0.94 on Friday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The firm has a market cap of $51.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The business’s 50-day moving average price is $0.92 and its 200 day moving average price is $1.02. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CTSO. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the third quarter worth $51,000. Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC raised its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.